TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company’s common shares.
About COSCIENS Biopharma Inc.
COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.
Issuer Contact:
Peter H. Puccetti
Interim CEO and Chairman of the Board
pp@cosciensbio.com
Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com
Investor Contact:
IR@cosciensbio.com



Đề xuất
PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026
A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time
HEARTBOT AI Wins Chunghwa Telecom Special Award at Meet Neo Star 2026
Allooloo Tops 100M Capital Markets AI Agent Traffic a Month
KONST Showcases “24/7 GPUs Delivered in Asia” at SC26, Offering AI Compute Services from Validation and Delivery to Round-the-Clock Operations
APEC CEO Summit 2026 Concludes Successfully in Shenzhen